Latest developments encircle research trials U3-1287 and U31287, assessing patritumab deruxtecan for the therapy of advanced ovarian cancer. Preliminary results shown at an medical conference indicates some clinical response, though challenges persist regarding optimal regimen and subject identification. More analysis are being conducted to thoroug